Robot-Assisted Surgery for Gastroesophageal Cancers is Transforming Patient Outcomes - Report - MDSpire

Robot-Assisted Surgery for Gastroesophageal Cancers is Transforming Patient Outcomes

Robot-assisted surgery (RAS) has led to shorter hospital stays, faster recovery and reduced pain for patients with many types of cancer. Now, thanks to the pioneering work of Moshim Kukar, MD, FACS, Department of Surgical Oncology, and his Roswell Park team, RAS is the standard of care for eligible patients with gastroesophageal junction cancers.

  • July 27, 2021

Share

Clinical Report: Robot-Assisted Surgery for Gastroesophageal Cancers

Overview

{'add': 'specific patient outcomes improved by RAS', 'remove': None, 'update': None}

Background

{'add': 'details on lifestyle factors contributing to cancer rise', 'remove': None, 'update': None}

Data Highlights

{'add': 'ensure correct table formatting', 'remove': None, 'update': None}

Key Findings

{'add': 'importance of patient education and referral', 'remove': None, 'update': None}

Clinical Implications

{'add': 'emphasize multidisciplinary team roles', 'remove': None, 'update': None}

Conclusion

{'add': 'importance of ongoing research', 'remove': None, 'update': None}

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. Author(s)/Org, Source, Year -- Title
  6. Updates in Surgery — Advancements in Esophagectomy: The Role of Robotic Assistance During the Abdominal Phase
  7. 2025 American Association for Thoracic Surgery expert consensus document
  8. Short-term outcomes of robot-assisted versus conventional minimally invasive esophagectomy
  9. Robotic versus laparoscopic distal gastrectomy for resectable gastric cancer: a randomized phase 2 trial | Nature Communications

Original Source(s)

Robot-Assisted Surgery for Gastroesophageal Cancers is Transforming Patient Outcomes

  • July 27, 2021

Related Content

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min
Epidemiology of bone cancer in Saudi Arabia: a nationwide population-based study (2004–2020)

Adrenal tumor microenvironment: hormone–immune crosstalk, molecular heterogeneity, and immunotherapeutic opportunities